Taiwan Bio Industry Organization (Taiwan BIO)’s Post

“How recent technological advancements such as spatial biology, single cell genomics, and complex in vitro models are revolutionizing the way drugs are developed." Upcoming Keynote Lecture David Walt, PhD, Scientific Founder of Illumina and Professor of Pathology at @Harvard Medical School.    I've had the pleasure to visit with David Walt in Boston and welcome him Toulouse when I was in the field of Electronic Noses (Pattern Recognition and Chemical sensors). Our paths have not crossed directly again. I recently realized we (Primetech Corporation) distributes ground breaking Spatial Biology Solutions from Vizgen in Japan where he is one of the founders. His Keynote Lecture is in Drug Discovery Day on April 3rd with Endpoints News. In the meantime, I recommend you check out last year’s Drug Discovery Day which I missed until yesterday. Fortunately, available on demand and still very relevant today. "The heat is on to find new ways to advance preclinical drug research" with David Grainger, Centessa Pharmaceuticals; Lorna Ewart, Emulate, Inc.; John Connolly, Parker Institute for Cancer Immunotherapy; John Carroll, Endpoints News. #preclinical #drugdiscovery #drugdevelopment #spatialbiology #singlecellgenomics #nams (by FDA)

Frontiers in Drug Delivery ( a multidisciplinary, DOAJ-indexed journal, see: https://lnkd.in/eTM87NVe ) invites articles from scientific fields pertinent to the development of in silico models addressing the several stages of intravascular drug delivery (IVDD) and including Molecular Dynamics (MD) and Coarse-Grained (CG) biomolecular and nanomaterial modelling (including molecular docking and bio-nano-informatic approaches), Physiologically based Pharmacokinetics (PBPK), Computational Fluid-Particle Dynamics (CFPD), Quantitative Structure-Activity Relations (QSAR) and Tissue Mechanics (TM) modelling, covering the study of a wide range of NCs such as liposomal, inorganic, polymeric, etc. Optimal-by-design nanocarrier in silico studies are also invited, as used in IVDD, including theragnostics and other modern biomedical applications. Submissions are welcome for the following article types: original research, review, mini-reviews, research protocol/method, opinion, and hypotheses.

An overview of the 𝗛𝗖𝗔𝗯 𝗣𝗟𝗨𝗦™ by Nona Biosciences💡 HCAb PLUS™ is the world’s first fully human heavy chain-only antibody (HCAb) platform, clinically validated and experimentally proven, and enables breakthrough in therapeutic modalities. 𝗞𝗲𝘆 𝗙𝗲𝗮𝘁𝘂𝗿𝗲𝘀: 🌟 HBICE® Technology — Unleashing bispecifics, multispecifics, immunocytokines, and other cutting-edge formats with enhanced structure, size reduction, and chain simplicity. 🌟 Breakthrough Therapeutic Modalities — Designed for powerful applications in ADCs, RDCs, PROTACs, and other areas demanding precision, efficiency, and adaptability. 🌟 Superior Performance in CAR Therapies — HCAbs from our HCAb Harbour Mice® deliver reduced immunogenicity, high solubility, tissue penetration, and conjugation benefits, ideal for advanced CAR-based cell therapies. 🌟 Pioneering mRNA Therapies & Targeted Delivery — The compact size and structural benefits of HCAbs enable next-level mRNA designs and LNP modifications, opening up new avenues in targeted treatments. Nona Biosciences is leading the way with highly stable, low-immunogenic, fully human HCAbs for breakthrough therapies. Explore the future of therapeutic innovation with HCAb PLUS™: https://lnkd.in/ecfYaq5u #antibodies #fullyhuman #fullyhumanantibodies #HCAb #heavychainonlyantibodies #heavychainantibodies #nextgentherapeutics #Therapeutics #NonaBiosciences #HCAbPLUS #BiotechInnovation #ImmuneTherapy #ADC #mRNAtherapey #CARTtherapy #CART

I am excited to announce the successful completion of a research topic in Frontiers in Bioengineering and Biotechnology. Stimuli-responsive lipid-bioactive conjugate-based nanocarriers: a smart approach in biomaterial applications https://lnkd.in/gpWNUvvg Stimuli-responsive lipid-bioactive conjugate-based nanocarriers are a revolutionary approach in biomaterial applications. These advanced nanosystems can remarkably adapt to various stimuli within the body, including pH, temperature, enzymes, and light. Their adaptability empowers precise control over drug release kinetics, minimizing unwanted effects while maximizing therapeutic efficacy. These smart nanocarriers have unparalleled efficiency in traversing physiological barriers and targeting specific cells or tissues, rendering them invaluable assets in drug delivery, imaging, and theranostics. They offer a sophisticated solution for personalized medicine and targeted therapy strategies, which hold great promise in treating various diseases. I would like to thank all the contributors and co-editors whose efforts made this achievement possible.

🔬📚 Exciting News! 📚🔬 Our first HTS paper was recently published in Advanced Healthcare Materials, with Maximilian Fusenig, PhD, Lisa Grönnert and me as joint first authors! https://lnkd.in/eD75AvPT In a close collaboration between the Leibniz-Institut für Polymerforschung Dresden (IPF) and the Ophthalmology Team at Roche, we developed Precision Culture Scaling (PCS-X), a statistics-driven approach to develop 3D cell cultures for high-throughput screening applications. Our methodology opens new avenues for creating HTS models of healthy and diseased tissues for drug discovery and individualized therapies. 🚀 Manfred Maitz, Maria Alejandra Ramirez Martinez, Manja Wobus, Uwe Freudenberg, Martin Bornhäuser, Jens Friedrichs, Peter Westenskow, Carsten Werner #Science #Research #DrugDiscovery #Vasculogenesis #HighThroughput

This article (https://lnkd.in/g-PBSr_n) in Nature Precision Oncology is a great perspective on the difference between an academic endeavor and a clinical one.  Whenever I show people the power of using interpretable #machinelearning with #singlecell data to identify potential biomarkers, I always make sure to follow up with a reminder that the ML model is just the starting point. At Singleron Biotechnologies, we understand that single-cell analysis is still a research tool and to make a clinical decision model, you need far more data sets than are available in the single-cell community. While we start with single-cell and interpretable ML, we always have an eye on converting single-cell results into flow or qPCR based tests that can be run on more samples and more routinely in a clinical setting. If you have a clinical research problem and you want help to find potential biomarkers that can eventually move into the clinic, come talk to us!  

🧬 Revolutionizing Drug Development: The Proteolipid Code 🧬 Researchers led by Professor Overduin have unveiled a pioneering framework that could transform how we understand and influence the interactions between proteins and lipid membranes—a breakthrough with profound implications for battling diseases like cancer and neurodegenerative disorders. Introducing "lipidons," a term inspired by genetic codons, this novel concept elucidates the intricate rules dictating lipid-protein interactions. This advancement is poised to revolutionize our strategies against illnesses characterized by misbehaving protein-membrane dynamics, such as Alzheimer's and Parkinson's disease. The proteolipid code enables us to anticipate how proteins are distributed within cells, revealing their affinity for binding to specific lipids. This insight is crucial for the design of targeted drugs and could lead to more precise and effective treatments. Taking it a step further, the team's technique of using polymers to extract and shape membrane sections into disk-like structures mimics actual cellular environments. This innovation allows for drug testing in conditions that closely resemble the biological settings where these membranes naturally exist, vastly improving the relevance of drug discovery assays. By classifying membrane structures into four distinct complexity levels, the research enriches our comprehension of cellular membrane architecture and function, shedding light on key processes like membrane fusion and division. 💡 This research paves the way for targeted therapies that interact with the very fabric of cellular life, opening a new frontier in our fight against some of the most challenging diseases. For those in #Pharmaceuticals, #Biotechnology, and #MedicalResearch, Overduin's proteolipid code is a reminder of the exciting innovations that lie at the intersection of biology and technology. #DrugDevelopment #ProteolipidCode #MedicalInnovation #CancerResearch #Neuroscience #Biopharma

Very delighted to share our forthcoming Special issue Editorial together with Christian Celia and Tambet (Tom) Teesalu on: "Unlocking the potential of nanomedicine: Advances in precision targeting strategies" Now available Drug Delivery and Translational Research, Maria Jose Alonso. We would like to express our sincere appreciation to all the authors who have contributed to this collection of articles, a total of 18 articles, 4 reviews and 14 original papers. This special issue is dedicated to nanomedicine and aimed to combine the expertise of a large number of scientists worldwide with extensive experience in nanomedicine, but also to discuss how fostering basic science into translational and personalized medicine for drug delivery applications. This can be achieved by a cutting-edge and multidisciplinary field of nanomedicine focused on innovative advancements to develop precise targeting strategies and unlock nanomedicine potentialities for precision medicine and relevant pre-clinical and clinical applications for different medical diseases. Hope you enjoy the reading (all articles are listed inside the Editorial for details): https://lnkd.in/eSjZn5nk

𝗠𝗮𝘁𝘂𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗵𝗶𝗣𝗦𝗖-𝗖𝗠𝘀 𝘄𝗶𝘁𝗵 𝗧𝟯 𝗮𝗻𝗱 𝗗𝗲𝘅: 𝗔 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲𝘅 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 🫀✅ If you are curious about how to enhance the maturation of hiPSC-CMs for applications such as disease modeling, drug discovery and cell therapy, you should take a look at our new application note, developed in partnership with Bayer, Fraunhofer IBMT, and Hamamatsu Photonics France. In this app note, we reveal how triiodothyronine (T3) and dexamethasone (Dex) can boost the structural and functional maturation of hiPSC-CMs. In this study, we used two complementary techniques, impedance / EFP and calcium imaging, to record calcium transients and electrical activity from the same hiPSC cardiomyocytes. Our findings corroborated previous studies, showing that drugs like triiodothyronine (T3) and dexamethasone modulate the electrical activity of these cells and enhance their calcium handling capacity, thus contributing to their maturation. We also showed how to employ the NSP-96 transparent plate to perform multiple assays and measure electrical activity, contractility and calcium transients of the same cell population, using the CardioExcyte 96 and the FDSS/μCELL. This way, you can obtain more data from fewer cells and minimize variability. If you want to know more about how to improve the maturation of hiPSC-CMs with T3 and Dex, you can access our full application note here: https://ow.ly/C7XM50QyixQ We are eager to hear your feedback and queries on this topic, so please feel free to leave a comment below or contact us directly. #Cardiomyocytes #CellAnalytics #CardioExcyte96 #hiPSC #StemCells

BioRestorative Therapies, Inc. reported that it has had substantive discussions with an undisclosed commercial stage regenerative medicine company with regard to a license of BioRestorative’s allogeneic, off-the-shelf ThermoStem ® metabolic intellectual property. Previously published peer-reviewed preclinical data from a study conducted in collaboration with the University of Utah School of Medicine demonstrated a clonogenic population of metabolically active brown adipose tissue (“BAT”) stem cells residing in adult humans that: 🔵Can be expanded in vitro 🔵Exhibit multilineage differentiation potential (osteogenetic, chondrogenic and adipogenic) 🔵 Functionally differentiate into metabolically active brown Adipocytes. 👉Read the full press release here: https://lnkd.in/gWThCrwk